Windtree Therapeutics (OTCMKTS: WINT) and Osiris Therapeutics (OTCMKTS:OSIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Risk and Volatility

Windtree Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Osiris Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.

Profitability

This table compares Windtree Therapeutics and Osiris Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -1,205.47% N/A -345.52%
Osiris Therapeutics N/A N/A N/A

Institutional & Insider Ownership

2.7% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are held by institutional investors. 3.5% of Windtree Therapeutics shares are held by company insiders. Comparatively, 44.6% of Osiris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Windtree Therapeutics and Osiris Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.04 million 2.30 -$39.49 million ($3.59) -0.09
Osiris Therapeutics $59.87 million 3.37 -$1.78 million N/A N/A

Osiris Therapeutics has higher revenue and earnings than Windtree Therapeutics.

Analyst Ratings

This is a summary of current ratings and price targets for Windtree Therapeutics and Osiris Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 0 0 2.00
Osiris Therapeutics 0 0 0 0 N/A

Summary

Osiris Therapeutics beats Windtree Therapeutics on 6 of the 8 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Receive News & Ratings for Windtree Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.